NYSE:ABBVBiotechs
Is AbbVie’s (ABBV) SKYRIZI Push and Apogee Deal Reframing Its Immunology-Centered Investment Story?
In recent weeks, AbbVie has highlighted the pending review of a subcutaneous induction option for SKYRIZI in Crohn’s disease, continued portfolio expansion through deals such as its roughly US$10.90 billion Apogee Therapeutics acquisition, and the ongoing recognition of its long-running immunology scholarship program.
Together, these developments underscore how heavily AbbVie’s outlook is tied to SKYRIZI’s future use, while it simultaneously invests in new therapies and reinforces its image...